secwatch.observer — SEC 8-K summary
======================================

Issuer:     BlossomHill Therapeutics, Inc. (BLSM)
CIK:        0001839970
Form:       8-K
Filed at:   2026-09-18T11:15:07+00:00
Accession:  0001193125-26-395031
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BlossomHill Q2 net loss $23.8M; IPO raises $168.3M; FDA Fast Track for lung cancer drug
--------------------------------------------------------------------------------

- Q2 2026 net loss $23.8M ($8.75/share) vs $13.2M ($5.51/share) in Q2 2025.
- R&D expenses $21.4M (up from $12.5M); G&A $3.3M (up from $1.6M).
- Cash $95.4M at June 30; August IPO gross proceeds $168.3M fund ops into Q2 2028.
- FDA Fast Track granted for BH-30643 in EGFR C797S-positive NSCLC after 3rd-gen TKI.
- Phase 1 SOLARA data: 45% ORR, 88% DCR in C797S-resistant patients; more milestones ahead.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1839970/000119312526395031/0001193125-26-395031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1839970/000119312526395031/d266261d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-395031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer